Foghorn Therapeutics (NASDAQ:FHTX – Get Free Report) had its target price lowered by research analysts at Morgan Stanley from $10.00 to $6.00 in a note issued to investors on Monday, Benzinga reports. The brokerage currently has an “equal weight” rating on the stock. Morgan Stanley’s price objective would indicate a potential upside of 51.52% from the stock’s previous close.
Separately, HC Wainwright reiterated a “buy” rating and set a $20.00 target price on shares of Foghorn Therapeutics in a research note on Monday, August 7th. One investment analyst has rated the stock with a hold rating and four have issued a buy rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $14.83.
Foghorn Therapeutics Price Performance
Hedge Funds Weigh In On Foghorn Therapeutics
Several hedge funds have recently bought and sold shares of the company. Tower Research Capital LLC TRC grew its stake in Foghorn Therapeutics by 300.4% during the 3rd quarter. Tower Research Capital LLC TRC now owns 4,921 shares of the company’s stock worth $25,000 after buying an additional 3,692 shares during the last quarter. UBS Group AG purchased a new stake in shares of Foghorn Therapeutics in the fourth quarter valued at $32,000. Wells Fargo & Company MN grew its position in Foghorn Therapeutics by 1,368.4% during the fourth quarter. Wells Fargo & Company MN now owns 5,389 shares of the company’s stock valued at $34,000 after acquiring an additional 5,022 shares during the period. Barclays PLC lifted its stake in shares of Foghorn Therapeutics by 533.5% during the fourth quarter. Barclays PLC now owns 5,397 shares of the company’s stock worth $34,000 after purchasing an additional 4,545 shares in the last quarter. Finally, Citigroup Inc. boosted its holdings in Foghorn Therapeutics by 1,321.0% in the second quarter. Citigroup Inc. now owns 6,778 shares of the company’s stock valued at $48,000 after purchasing an additional 6,301 shares during the last quarter. Institutional investors and hedge funds own 63.94% of the company’s stock.
Foghorn Therapeutics Company Profile
Foghorn Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system.
- Five stocks we like better than Foghorn Therapeutics
- Investing in the Best Airline Stocks
- Analyst says Archer Aviation may double. Is it time to buy?
- What is a Secondary Public Offering? What Investors Need to Know
- Alibaba’s bottom is in: Analysts see a monster rally ahead
- What is Forex and How Does it Work?
- TripAdvisor is on AI-powered recovery from record lows
Receive News & Ratings for Foghorn Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Foghorn Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.